Search
Home
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Great Place To Work
Analytics
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Home
Latest
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Rankings
Great Place To Work
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Paula Doenecke
Stay informed with Paula Doenecke’s coverage and analysis for Fortune.
Retail
Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
By
Paula Doenecke
,
Naomi Kresge
, and others
Finance
Swatch profit plunges almost 75%, hit by weakness in China
By
Paula Doenecke
and
Bloomberg
Politics
Germany issues arrest warrant for Ukrainian named ‘Volodymyr Z’ over Nord Stream pipeline sabotage
By
Natalia Ojewska
,
Paula Doenecke
, and others
Finance
Switzerland shouldn’t follow Europe’s lead on tax, says Roche CEO. Instead, it must compete with ‘Dubai, China and India’
By
Paula Doenecke
and
Bloomberg
Finance
Amid U.S. construction boom, world’s largest cement maker will spin off North American business, seek $30B valuation: ‘Two independent champions’
By
Allegra Catelli
,
Paula Doenecke
, and others
Finance
Roche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
By
Paula Doenecke
and
Bloomberg